Related Experiment Videos
Fistula treatment: The unresolved challenge
Stephan R Vavricka1, Gerhard Rogler
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland. klisaacs@med.unc.edu
Digestive Diseases (Basel, Switzerland)
|October 8, 2010
Summary
Fistulas affect up to 50% of Crohn's disease patients, causing significant morbidity. Current treatments include antibiotics, immunosuppressants, anti-TNF agents, and surgery, but challenges remain in classification and treatment efficacy.
Area of Science:
- Gastroenterology
- Inflammatory Bowel Disease
- Surgical Gastroenterology
Background:
- Fistulas are a common and debilitating complication of Crohn's disease, affecting up to 50% of patients.
- These complications lead to significant morbidity, including tissue destruction and functional disability.
Purpose of the Study:
- To review current medical and surgical treatment options for fistulizing Crohn's disease.
- To highlight the challenges in fistula classification and the need for further research.
Main Methods:
- Review of existing literature on Crohn's disease fistulas.
- Analysis of current therapeutic strategies, including pharmacological and surgical interventions.
- Discussion of treatment outcomes and limitations.
Main Results:
- Internal fistulas may be asymptomatic or require surgery; perianal fistulas can be managed with antibiotics, immunosuppressants, or anti-TNF agents.
- Surgery is indicated for sepsis, refractory disease, or complications, with options including drainage, ileostomy, or proctectomy.
- Limited data exist for newer agents like cyclosporine A, tacrolimus, or methotrexate, positioning them as second-line therapies.
Conclusions:
- Treatment selection for Crohn's disease fistulas depends on fistula type, severity, and location.
- A standardized classification system and further randomized controlled trials are crucial for advancing treatment strategies.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:25Urinary Tract Calculi VI: Surgical Management
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...